Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Long-Term Investments (2023 - 2025)

Maxcyte (MXCT) has disclosed Long-Term Investments for 3 consecutive years, with $52.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments rose 22.14% to $52.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $52.3 million, a 22.14% increase, with the full-year FY2024 number at $35.8 million, down 16.67% from a year prior.
  • Long-Term Investments was $52.3 million for Q3 2025 at Maxcyte, up from $38.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $52.3 million in Q3 2025 to a low of $18.4 million in Q3 2023.
  • A 3-year average of $39.4 million and a median of $42.5 million in 2024 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 132.23% in 2024, then dropped 19.12% in 2025.
  • Maxcyte's Long-Term Investments stood at $42.9 million in 2023, then decreased by 16.67% to $35.8 million in 2024, then skyrocketed by 46.09% to $52.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Long-Term Investments are $52.3 million (Q3 2025), $38.6 million (Q2 2025), and $36.4 million (Q1 2025).